Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Apr 08, 2022 1:05pm EDT

Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting

Mar 16, 2022 7:00am EDT

Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors

Feb 09, 2022 6:30am EST

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting

Feb 08, 2022 7:00am EST

Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update

Dec 17, 2021 6:30am EST

Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update

Aug 30, 2021 4:01pm EDT

Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)

Aug 19, 2021 9:35pm EDT

Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering

Aug 16, 2021 6:30am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Jun 14, 2021 7:45am EDT

Sonnet BioTherapeutics Announces Change in Date of Annual Meeting

Jun 08, 2021 4:30pm EDT

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

1...
4
5
6
7
8
9
10
11
12
13